anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To provide a new safe lipase activity inhibitor, a cosmetic composition, a drink, and a food. SOLUTION: This lipase activity inhibitor is characterized by containing the extract of one or more plants selected from Hypericum erectum and Belamcanda chinensis. The cosmetic composition, drink or food is characterized by containing the lipase activity inhibitor. The lipase activity inhibitor can inhibit the activity of lipase, and can significantly eliminate and inhibit active oxygen. The cosmetic composition can improve eczema, pimples and chapped skins, give tensions and gloss to skins, and effectively prevent the ageing of skins and scalps. The lipase activity inhibitor is safe for human beings or animals in the form of internal preparations or external preparations, and can be applied to all the forms of the preparations (medicines, quasi drugs, cosmetics, foods).
Atrophic kidney-like lesion (AKLL) is a rare kidney lesion, which was recently suggested by the Genitourinary Pathology Society as a provisional entity. As of now, 16 examples of AKLL have been described in the literature. Here we report a new tumor which shows similar clinicopathologic characteristics with those previously reported in AKLL. Immunohistochemical (IHC) studies in the current lesion identified a biphasic staining pattern consisting of a mixture of WT1+/KRT7-/PAX8- large dilated cysts and WT-/KRT7+/PAX8+ small atrophic cysts. Histomorphologic features of AKLL overlap with several neoplastic and non-neoplastic entities which can lead to mischaracterization. Awareness of the differentiating features is likely important when evaluating these lesions.
BACKGROUND: Statins, previously rated as pregnancy category X agents, were contraindicated during pregnancy due to the teratogenic effects observed in animal studies. However, it is still controversial whether statins have detrimental impact on pregnant women or not, and some studies even suggest a potential benefit of statin use against pregnancy complications. The aim of this study was to explore whether maternal exposure to statins is associated with increased rates of pregnancy-related adverse events (AEs), including abortion, abortion spontaneous, preterm birth, low birth weight, stillbirth/fetal death, and fetal complications.
RESEARCH DESIGN AND METHODS: Data from 1 January 2004 to 30 June 2022 were extracted through the U.S. FDA Adverse Event Reporting System (FAERS) database, to conduct disproportionality analysis and Bayesian analysis by reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN) algorithms. To identify the potential risks of pregnancy-related AEs, each statin was compared to all the other drugs, all the other statins, and the reference drugs (fenofibrate and evolocumab).
RESULTS: A total of 477 cases involving pregnancy-related AEs associated with stains were submitted to the FAERS database by healthcare professionals. No obvious disproportionate association of abortion, abortion spontaneous, or stillbirth/fetal death was identified for all statins during gestation. In comparison with all the other drugs, lovastatin showed an increased risk of fetal complications (ROR = 2.45, 95% CI, 1.22-4.95; IC025 = 0.63), and pravastatin demonstrated increased risks of preterm birth (ROR = 4.89, 95% CI, 3.65-6.54; IC025 = 1.69) and low birth weight (ROR = 9.60, 95% CI, 5.56-16.56; IC025 = 1.88). Similar results were found when compared lovastatin or pravastatin with fenofibrate. Furthermore, statins were associated with higher proportion of fetal complications and preterm birth when comparing with evolocumab.
CONCLUSIONS: Statins did not increase the risk of pregnancy-related AEs, including abortion, abortion spontaneous, or stillbirth/fetal death. However, we did find significant disproportionality signals for preterm birth and low birth weight associated with pravastatin, and lovastatin was related to a higher proportion of fetal complications. The results in this study may provide evidence on the safety of statins during pregnancy, which need to be verified in further investigations.
The invention belongs to the technical field of medicine and discloses a salvia miltiorrhiza total phenolic acid pill and a preparation method thereof. The salvia miltiorrhiza total phenolic acid pill consists of salvia miltiorrhiza total phenolic acid as active ingredient and drug carriers. In the pill, the salvia miltiorrhiza total phenolic acid accounts for 5 to 95 percent, which is combined with the proper amount of the drug carriers according to arbitrary proportion. The drug carriers are carriers such as polyethylene glycol (the molecular weight is 200 to 20,000), polysorbate (the molecular weight is 10 to 80), stearic acide, sodium stearate, etc. A better content range of the pill is that the salvia miltiorrhiza total phenolic acid is 20 to 60 percent and the rest is stroma; the stroma is the material like polyethylene glycol and two or more than two kinds of the material which are mixed according to arbitrary proportion. The pill of the invention is characterized by fast healing effect and little side effect. In the producing process of the pill, no dust is produced, little auxiliary material is needed, the producing process is short, the quality is stable and the pill is easy to use.
The invention discloses a multifunctional tooth implantation assisting device and a method for manufacturing a metal inner crown by utilizing the same. The multifunctional tooth implantation assisting device comprises a base tooth and a positioning cap. The base tooth comprises a positioning seat and a supporting column. The positioning seat is arranged in a positioning groove formed in an implantation body and is provided with a first penetrating hole. The supporting column is connected to the positioning seat in an integrally formed mode and is provided with a second penetrating hole communicated to the first penetrating hole, and the second penetrating hole is greater than the first penetrating hole in hole diameter. The positioning cap is detachably arranged on the base tooth in a sleeving mode and comprises a healing portion and a positioning portion. The healing portion corresponds to the supporting column and tightly attaches to the supporting column, the positioning portion is connected to the healing portion in an integrally formed mode and is provided with a third penetrating hole, and the third penetrating hole is communicated to the second penetrating hole. The multifunctional tooth implantation assisting device has the functions of healing the cap and reprinting gingival and can be also used as a temporary inner crown. In addition, the multifunctional tooth implantation assisting device can be further used for manufacturing the metal inner crown.
Finely divided particles of budesonide are used in therapeutic administration by inhalation where it is desired that the drug particles penetrate deep into the lung. Finely divided, substantially crystalline particles of budesonide which have a mass median diameter (MMD) of less than 10 microns are described and characterised in that they are substantially smooth and have a BET gas absorption value from 1 to 4.5 m2/g. The well-defined small particles described are a prerequisite for an efficient formulation for inhalation, which may be observed by, e.g. an increased fraction of the dose to the lung.  Crystals with a low surface area have lower tendency to stick together than crystals with a higher surface area e.g. irregular crystals. A process for the preparation of the budesonide particles, a pharmaceutical composition comprising the particles, the use of the particles in the manufacture of a medicament for use in the treatment of a respiratory disorder, such as asthma, is also described.
PROBLEM TO BE SOLVED: To obtain a hair-decoloring agent little in the damage to hair, giving strong and uniform decoloration effects, and good in the finished appearance. SOLUTION: This hair-decoloring agent contains 1-50wt.% of a persulfate salt (e.g. sodium persulfate), 0.1-20wt.% of an oxidizing agent (e.g. hydrogen peroxide), and 0.01-10wt.% of a higher alcohol (e.g. stearyl alcohol) as active ingredients. It is essential that the total amount of a lower alcohol (e.g. ethanol) and a polyhydric alcohol (e.g. polyethylene glycol) is <=10% on the employment of the hair-decoloring agent. The addition of the higher alcohol accelerates the spreading and impregnation of the agent liquid into the hair. The control of the hole amount of the lower alcohol and the polyhydric alcohol to <=10% enables to uniformly and strongly decolor the hairs ranging from the high temperature root parts to the relatively low temperature hair tip parts, and further improves the finishing appearance.  The addition of a cationic surfactant or a cationized polymer extremely improves the hair-protecting action and the finishing appearance.
Oral daily placebo for 3 months compared to pioglitazone for 3 months, then crossover after a 2 month washout. Similar doses as mentioned above.
Liver disease accounts for approximately 2 million deaths er year worldwide. Liver fibrisis results from chronic injury to the liver. If not effectively treated in time, liver fibrosis may transform into liver cirrhosis. MVs are recognized as potential biomarkers and important theraputic tools for a wide sectrum of diseases. Medical ozone has the ability to protect the body against pathological conditions caused by oxidative stress. The influence of ozone and MVs on CCL4 induced liver fibrosis was investigated in this study. Forty-eight adult male albino rats were divided into four equal groups. I control, II CCL4 group, III ozone and IV microvesicles groups. Liver fibrosis was induced in group II, III & IV using 12 SC injections (0.5 ml/kg body weight) of CCL4 dissolved in olive oil twice ber week for weeks. Blood samples were obtained to estimate serum ALT & AST. Liver tissues were processed for measurment of GSH & SOD, light and electron microscopic examination. H&E staine sections og group II showed dilated congested sinusoids and centralveins, mononuclear infiltrations, vacuolations and dark nuclei. Ultrastructurally, group II revealed irregular heterochromatic nuclei of hepatocytes, small scanty mitochondria & vacuolations. Morphometric & statistical analyses were performed. Group III showed some improvement, however, group IV showed more imrovement. The results indicates that MVs caused marked improvement than ozone against CCL4 induced liver damage via antioxidant & antiinflammatory properties.
The objectives of this study were to determine efficacy of hearing aids in older adults using audiology best practices, to evaluate the efficacy of an alternative over-the-counter (OTC) intervention, and to examine the influence of purchase price on outcomes for both service-delivery models. The design of this study was a single-site, prospective, double-blind placebo-controlled randomized trial with three parallel branches: (a) audiology best practices (AB), (b) consumer decides OTC model (CD), and (c) placebo devices (P). Outcome measures were obtained after a typical 6-week trial period with follow-up 4-week AB-based trial for those initially assigned to CD and P groups.

Older adults from the general community were recruited via newspaper and community flyers to participate at a university research clinic. Participants were adults, ages 55-79 years,with mild-to-moderate hearing loss. Intervention(s): All participants received the same highenddigital mini-behind-the-ear hearing aids fitted bilaterally.AB and P groups received best-practice services from audiologists; differing mainly in use of appropriate (AB) or placebo (P) hearing aid settings. CD participants self-selected their own pre-programmed hearing aids via an OTC model. Primary outcome measure was a 66-item self-report, Profile of Hearing Aid Performance/Benefit. Secondary outcome measure was the Connected Speech Test benefit.
PROBLEM TO BE SOLVED: To obtain a suppository containing a benzimidazole derivative and cysteine hydrochloride, excellent in preservation stability and absorptivity in the rectum and used as a serotonin3 receptor antagonist. SOLUTION: This suppository contains both 6-amino-5-chloro-1-isopropyl-2-(4- methyl-1-pyperadyl)benzimidazole of the formula and cysteine hydrochloride or its hydrate as active ingredients. The components are dissolved or dispersed in a suppository base and formed into the suppository with an optionally added additive such as a surfactant by the conventional method. The cysteine hydrochloride is blended in 1-300 pts.wt. and the suppository base is blended in 10-20,000 pts.wt. based on 1 pt.wt. compound of the formula. The divided dose of the compound of the formula is 0.1-100mg and the dairy dose is 1-3 times of the divided dose. The suppository can be dosed to a patient impossible to swallow down a medicine because of vomiting and impossible to be dosed by injection.
INTRODUCTION: Enhanced Recovery After Surgery (ERAS) guidelines in adults have demonstrated reduced complications, length of stay, and cost. However, neonatal ERAS studies are limited and translation of adult ERAS guidelines to neonates is challenging. Furthermore, the knowledge, perception, and practice of neonatal ERAS guidelines is largely unknown. Our aim is to address this practice gap by determining current practice of the 2020 neonatal intestinal surgery ERAS guidelines at our institution and evaluating postoperative outcomes.
METHODS: A retrospective study was conducted of patients <1 y who underwent elective ostomy takedown at a single-center tertiary children's hospital between 2013 and 2023. A 13-point ERAS score was developed. Demographics, clinical course, pain management, nutrition, ERAS scores, and outcomes were analyzed using descriptive statistics, logistic and negative binomial regression.
RESULTS: One hundred eighty-six patients met the inclusion criteria. At surgery, the median age was 124 d (interquartile range [IQR] 81-220) and median weight was 4360 g (IQR 2920-7200). The median ERAS score was 6 (IQR 5-7). The highest scores were for appropriate (97.9%) and timely (91.9%) prophylactic antibiotics, and the lowest for preventing intraoperative hypothermia (14.5%), limiting opioids (9.1%), and early enteral feeding postoperatively (24.7%). Surgical site infection occurred in 14.5% and median length of stay was 28 (IQR 5-127) d.
CONCLUSIONS: Our institution's current practice of the 2020 neonatal intestinal surgery ERAS guidelines was poor. We identified opportunities for improvement including postoperative antibiotic administration, prevention of intraoperative hypothermia, nutrition, and pain management. Future studies will focus on implementation of neonatal ERAS guidelines at our institution and evaluation of adherence and outcomes.
318,268. Heilbron, I. M. March 2, 1928. Vitamins. - Ergosterol and like sterols are rendered antirachitically active by treatment with metallic catalysts such as copper, nickel, or alloys such as copper bronze, without employing ultraviolet light. Preferably risk of oxidation is avoided by conducting the operation in a vacuum or in an inert atmosphere. In an example ergosterol mixed with finely-divided bronze is heated to 250-300‹ C. in a vessel evacuated to 3 mm. pressure for 30-60 minutes. The weight of bronze used is 2-3 times tne weight of the erysterol. The mixture is dissolved in ether, the bronze separated, and the ether distilled off.
Dapagliflozin is an oral medication used to treat Type 2 diabetes. It belongs to a sodium-glucose cotransporter 2 (SGLT2) inhibitors.
patients who require a thyroidectomy will be enrolled after informed consent will begiven. Prior to thyroidectomy, patients will be randomized to two groups: 1) use of conventional surgical procedures to achieve hemostasis,i.e., ligatures and bipolar electrocauterization alone, and 2) use of oxidized cellulose patch (Surgicel©) in addition to classical methods (ligature; bipolar electrocautery). All anticoagulants will be discontinued 10 days prior to the operation, if this will not be possible the patient will be excluded. The investigators will perform the specified procedure in accordance with accepted clinical practice standards. At the end of the thyroidectomy, a meticulous hemostasis will be achieved. Before wound closure, the sealed affiliation envelopes will be opened and 1-2×2 cm oxidized cellulose patch will be placed over the thyroid bed depending on patient randomization. Next, a suction drain will be placed. The drains will be removed when the secretion volume/day will be less than 20 cc.

All operations will be performed under general anesthesia by three head and neck surgeons who had experience in thyroid surgery. Outcome measures will include duration of operation, hemodynamic variables on emergence (blood pressure and heart rate), volume of secretion in the drain, time to removal of wound drain, length of postoperative hospital stay, and incidence of postoperative complications, i.e. hemorrhage, transient hypoparathyroidism, wound infection, seroma, and recurrent laryngeal nerve palsy. Evaluation of the postoperative course and recording of data will be done by one surgeons blinded to the intervention (MA). Follow-up for this study will be ended one month after the surgery.
The present invention relates to an extraction method of an active protein secretion liquid of living scorpion, which is applied to protein extraction in the production of medicines. Firstly, living scorpion is disinfected; the needle head of an injector is inserted into the protein bag at the middle position of the fifth section of the post abdomen in the scorpion to extract raw liquids before protein secretion, during protein secretion and after protein secretion of the living scorpion; then, the digestive juice extracted from the self body, the internal body and the external body of the living scorpion is added into the raw liquids of protein secretion of the living scorpion for separation and extraction. The protein secretion liquid obtained by the method is high in activity, and the operation is simple and convenient. The protein secretion liquid contains various amino acids, crude proteins and rich trace elements required by human bodies. The protein secretion liquid can be prepared into a wine base or water base oral liquid of a certain proportion so that the shelf life of active protein can be prolonged. The protein secretion liquid can also be directly used for treating various diseases without toxic or side effect.
Cases of severe hepatocellular injury, including fulminant liver failure resulting in death, have been reported in postmarketing use. As of May 2005, three cases of fatal fulminant hepatic failure have been reported from more than 40,000 patient years of worldwide use. This incidence may be 10- to 100-fold higher than the background incidence in the general population. All three cases were reported within the first six months of initiation of treatment with TASMAR. Analysis of the laboratory monitoring data in over 3,400 TASMAR-treated patients participating in clinical trials indicated that increases in SGPT/ALT or SGOT/AST, when present, generally occurred within the first 6 months of treatment with TASMAR.

The imprecision of the estimated increase is due to uncertainties about the base rate and the actual number of cases occurring in association with TASMAR. The incidence of idiopathic potentially fatal fulminant hepatic failure (i.e., not due to viral hepatitis or alcohol) is low. One estimate, based upon transplant registry data, is approximately 3/1,000,000 patients per year in the United States. Whether this estimate is an appropriate basis for estimating the increased risk of liver failure among TASMAR users is uncertain. TASMAR users, for example, differ in age and general health status from candidates for liver transplantation. Similarly, underreporting of cases may lead to significant underestimation of the increased risk associated with the use of TASMAR.

During the premarketing development of tolcapone, two distinct patient populations were studied, patients with end-of-dose wearing-off phenomena and patients with stable responses to levodopa therapy. All patients received concomitant treatment with levodopa preparations, however, and were similar in other clinical aspects. Adverse reactions are shown for these two populations combined.

The most commonly observed adverse reactions in the double-blind, placebo-controlled trials (N=892), with a difference in incidence (TASMAR minus Placebo) of at least 5% or greater in the 100 mg or 200 mg TASMAR-treated groups compared to placebo, were dyskinesia, nausea, diarrhea, anorexia, sleep disorder, vomiting, urine discoloration, somnolence, hallucination, dystonia, and sweating.

Approximately 16% of the 592 patients who participated in the double-blind, placebo-controlled trials discontinued treatment due to adverse reactions compared to 10% of the 298 patients who received placebo. Diarrhea was by far the most frequent cause of discontinuation (approximately 6% in tolcapone patients vs. 1% on placebo).
The effects of sublingual asenapine on the QT/QTc interval were evaluated in a dedicated adult QT study. This trial involved sublingual asenapine doses of 5 mg, 10 mg, 15 mg, and 20 mg twice daily, and placebo, and was conducted in 151 clinically stable patients with schizophrenia, with electrocardiographic assessments throughout the dosing interval at baseline and steady state. At these doses, sublingual asenapine was associated with increases in QTc interval ranging from 2 to 5 msec compared to placebo. No patients treated with sublingual asenapine experienced QTc increases ≥60 msec from baseline measurements, nor did any patient experience a QTc of ≥500 msec.

Electrocardiogram (ECG) measurements were taken at various time points during the SECUADO clinical trial (3.8 mg/24 hours and 7.6 mg/24 hours doses). In the placebo-controlled trial, there were no reports of QT prolongations exceeding 500 msec for SECUADO and placebo.

There were no reports of Torsades de Pointes or any other adverse reactions associated with delayed ventricular repolarization with sublingual asenapine or with SECUADO.

The use of SECUADO should be avoided in combination with other drugs known to prolong QTc including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and antibiotics (e.g., gatifloxacin, moxifloxacin). SECUADO should also be avoided in patients with a history of cardiac arrhythmias and in other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including bradycardia; hypokalemia or hypomagnesemia; and presence of congenital prolongation of the QT interval.
Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles. Patients will be evaluated for response every 8 weeks. Patients with disease progression will be taken off the study.